GlassScriptPhysician profile
Michael Manuel Malmer
NPI 1073597472
$1,016.75
in general payments reported to CMS, 2019-2025
22 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $130 · 2023: $186 · 2024: $116 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $443.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $215.00 | 2019-2020 | |
| Novo Nordisk INC | $139.08 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $109.49 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $89.90 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $69.11 | 2020 | |
| Pfizer INC. | $51.73 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.90 | 2023 | Ofev, Jardiance, Tradjenta |
| Esperion Therapeutics, INC. | $35.85 | 2023 | Nexletol |
| Exact Sciences Corporation | $32.57 | 2025 | The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $30.81 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $25.73 | 2019 | |
| Genentech USA, INC. | $24.39 | 2019 | |
| Axsome Therapeutics, INC. | $23.30 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $17.89 | 2025 | Rexulti |
| Astellas Pharma US INC | $17.38 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $17.08 | 2023 | Eliquis |
| Glaxosmithkline, LLC. | $14.78 | 2023 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $14.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.06 | 2019 | |
| Globus Medical, INC. | $13.20 | 2023 | Retrieve |
| Abbott Laboratories | $12.80 | 2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Malmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.